CL2020001564A1 - Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina. - Google Patents
Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina.Info
- Publication number
- CL2020001564A1 CL2020001564A1 CL2020001564A CL2020001564A CL2020001564A1 CL 2020001564 A1 CL2020001564 A1 CL 2020001564A1 CL 2020001564 A CL2020001564 A CL 2020001564A CL 2020001564 A CL2020001564 A CL 2020001564A CL 2020001564 A1 CL2020001564 A1 CL 2020001564A1
- Authority
- CL
- Chile
- Prior art keywords
- receptor
- compounds
- triazolobenzazepines
- vasopressin
- receptor antagonists
- Prior art date
Links
- 102000004136 Vasopressin Receptors Human genes 0.000 title 1
- 108090000643 Vasopressin Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- WAYZQLIRXHPOCN-UHFFFAOYSA-N 5,6-dihydro-4h-[1,2,4]triazolo[4,3-a][1]benzazepine Chemical class C1CCC2=NN=CN2C2=CC=CC=C21 WAYZQLIRXHPOCN-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a derivados de 5,6-dihidro-4H-[1,2,4]triazolo[4,3-a][1]benzazepina de fórmula general (I) y/o sus sales y/o sus isómeros geométricos y/o sus estereoisómeros y/o sus enantiómeros y/o sus racematos y/o sus diastereómeros y/o sus metabolitos biológicamente activos y/o sus profármacos y/o sus solvatos y/o sus hidratos y/o sus polimorfos, que son moduladores del receptor V1a que actúan central y/o periféricamente, particularmente antagonistas del receptor V1a.. Es otro objeto de la presente invención el proceso para la preparación de los compuestos, y también los intermediarios para el proceso de preparación. La invención también se refiere a las composiciones farmacéuticas que contienen los compuestos o junto con uno o más principios activos adicionales, así como también al uso en el tratamiento y/o profilaxis de una enfermedad o afección asociada con la función del receptor V1a
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1700521A HU231206B1 (hu) | 2017-12-15 | 2017-12-15 | Triazolobenzazepinek |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020001564A1 true CL2020001564A1 (es) | 2020-11-06 |
Family
ID=89992589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001564A CL2020001564A1 (es) | 2017-12-15 | 2020-06-11 | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina. |
Country Status (22)
Country | Link |
---|---|
US (1) | US11298363B2 (es) |
EP (1) | EP3724192B1 (es) |
JP (1) | JP7428647B2 (es) |
KR (1) | KR20200100111A (es) |
CN (1) | CN111479813B (es) |
AR (1) | AR113933A1 (es) |
AU (1) | AU2018385724B2 (es) |
BR (1) | BR112020011880A2 (es) |
CA (1) | CA3085562A1 (es) |
CL (1) | CL2020001564A1 (es) |
CU (1) | CU24630B1 (es) |
EA (1) | EA202091344A1 (es) |
HU (1) | HU231206B1 (es) |
IL (1) | IL275084B2 (es) |
JO (1) | JOP20200149B1 (es) |
MX (1) | MX2020006204A (es) |
PE (1) | PE20210671A1 (es) |
PH (1) | PH12020500548A1 (es) |
SG (1) | SG11202005299VA (es) |
TN (1) | TN2020000083A1 (es) |
TW (1) | TWI826406B (es) |
WO (1) | WO2019116324A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物 |
TWI804119B (zh) * | 2020-12-21 | 2023-06-01 | 大陸商上海濟煜醫藥科技有限公司 | 三氮唑類三并環衍生物及其製備方法和應用 |
HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
WO2023164710A1 (en) * | 2022-02-28 | 2023-08-31 | The Trustees Of Columbia University In The City Of New York | Avpr1a blockade to reduce social isolation-induced anxiety in females |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2056259T3 (es) | 1989-02-10 | 1994-10-01 | Otsuka Pharma Co Ltd | Derivados de carboestirilo. |
FR2679903B1 (fr) | 1991-08-02 | 1993-12-03 | Elf Sanofi | Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant. |
ATE277003T1 (de) | 1993-07-21 | 2004-10-15 | Yamanouchi Pharma Co Ltd | Zwischenprodukt zur herstellung von kondensierten benzazepinderivate |
ES2199251T3 (es) | 1994-06-15 | 2004-02-16 | Otsuka Pharmaceutical Company, Limited | Derivados benzoheterociclicos utilizables como moduladores de vasopresina o de oxitocina. |
FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
BR0110961A (pt) | 2000-05-19 | 2004-06-29 | Merck Patent Gmbh | Derivados de triazol |
ATE305454T1 (de) | 2000-07-05 | 2005-10-15 | Ortho Mcneil Pharm Inc | Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten |
US7056910B2 (en) | 2000-11-28 | 2006-06-06 | Astellas Pharma Inc. | 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof |
CN105712985A (zh) | 2001-10-12 | 2016-06-29 | 阿泽范药品公司 | β-内酰胺后叶加压素V1a拮抗剂 |
JP2005104838A (ja) | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
DK1597260T3 (da) * | 2003-02-19 | 2007-04-02 | Pfizer | Triazol forbindelser, der er anvendelige i behandling |
GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
GB0325021D0 (en) * | 2003-10-27 | 2003-12-03 | Pfizer Ltd | Therapeutic combinations |
EP1701959A1 (en) | 2003-12-22 | 2006-09-20 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
MX2007002248A (es) | 2004-08-25 | 2008-10-02 | Pfizer | Triazolobenzodiazepinas y su uso como antagonistas de vasopresina. |
WO2006072458A2 (de) | 2004-12-31 | 2006-07-13 | Abbott Gmbh & Co. Kg | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung |
WO2006100082A2 (de) | 2005-03-24 | 2006-09-28 | Abbott Gmbh & Co. Kg | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung |
ES2434467T3 (es) | 2005-05-13 | 2013-12-16 | Lexicon Pharmaceuticals, Inc. | Compuestos multicíclicos y métodos para su uso |
SI1904477T1 (sl) | 2005-07-14 | 2009-06-30 | Hoffmann La Roche | Derivati indol-3-karbonil-spiro-piperidina kot antagonisti V1A receptorja |
PT1912976E (pt) | 2005-07-21 | 2009-01-07 | Hoffmann La Roche | Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a |
WO2007014851A2 (en) | 2005-07-29 | 2007-02-08 | F. Hoffmann-La Roche Ag | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
DE102006051796A1 (de) * | 2006-11-03 | 2008-05-08 | Merck Patent Gmbh | Triaza-benzo[e]azulenderivate |
JP2010517966A (ja) | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 摂食障害の処置のための1−オキサ−3−アザスピロ(4.5)デカン−2−オンおよび1−オキサ−3,8−ジアザスピロ(4.5)デカン−2−オン誘導体 |
TWI459947B (zh) | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
MX2011005596A (es) | 2008-11-28 | 2011-06-16 | Hoffmann La Roche | Arilciclohexileteres de dihidro-tetraazabenzoazulenos para uso como antagonistas del receptor de vasopresina via. |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
TW201103907A (en) | 2009-03-20 | 2011-02-01 | Lundbeck & Co As H | Amide derivatives as neuropeptide Y5 receptor ligands |
EP2495236A4 (en) | 2009-10-26 | 2013-03-27 | Otsuka Pharma Co Ltd | BENZAZEPINE COMPOUND |
GB201004677D0 (en) | 2010-03-19 | 2010-05-05 | Vantia Ltd | New salt |
US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
US8492376B2 (en) * | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
WO2011143150A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
BR112013012072A2 (pt) * | 2010-11-15 | 2016-08-16 | Agenebio Inc | derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos |
CN104781259B (zh) * | 2012-09-28 | 2018-06-01 | 拜耳制药股份公司 | 抑制bet蛋白的5-芳基三唑并氮杂* |
WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
PE20180227A1 (es) | 2014-12-09 | 2018-01-31 | Bayer Ag | Benzamidas sustituidas con 1,3-tiazol-2-ilo |
US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
EP3319959B1 (en) | 2015-07-06 | 2021-09-01 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
CN106349241B (zh) * | 2015-07-15 | 2020-04-21 | 上海翰森生物医药科技有限公司 | 具有hsp90抑制活性的三唑衍生物及其制备方法和应用 |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
AR108265A1 (es) | 2016-05-03 | 2018-08-01 | Bayer Pharma AG | Derivados de feniltriazol sustituidos con amida y usos de estos |
WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
-
2017
- 2017-12-15 HU HU1700521A patent/HU231206B1/hu unknown
-
2018
- 2018-12-12 TW TW107144774A patent/TWI826406B/zh active
- 2018-12-13 AR ARP180103643A patent/AR113933A1/es unknown
- 2018-12-14 CN CN201880080932.8A patent/CN111479813B/zh active Active
- 2018-12-14 EA EA202091344A patent/EA202091344A1/ru unknown
- 2018-12-14 TN TNP/2020/000083A patent/TN2020000083A1/en unknown
- 2018-12-14 CA CA3085562A patent/CA3085562A1/en active Pending
- 2018-12-14 BR BR112020011880-0A patent/BR112020011880A2/pt unknown
- 2018-12-14 CU CU2020000048A patent/CU24630B1/es unknown
- 2018-12-14 AU AU2018385724A patent/AU2018385724B2/en active Active
- 2018-12-14 KR KR1020207020172A patent/KR20200100111A/ko not_active Application Discontinuation
- 2018-12-14 WO PCT/IB2018/060077 patent/WO2019116324A1/en active Application Filing
- 2018-12-14 JP JP2020532928A patent/JP7428647B2/ja active Active
- 2018-12-14 SG SG11202005299VA patent/SG11202005299VA/en unknown
- 2018-12-14 EP EP18836400.4A patent/EP3724192B1/en active Active
- 2018-12-14 US US16/954,085 patent/US11298363B2/en active Active
- 2018-12-14 MX MX2020006204A patent/MX2020006204A/es unknown
- 2018-12-14 JO JOP/2020/0149A patent/JOP20200149B1/ar active
- 2018-12-14 PE PE2020000640A patent/PE20210671A1/es unknown
-
2020
- 2020-06-03 IL IL275084A patent/IL275084B2/en unknown
- 2020-06-09 PH PH12020500548A patent/PH12020500548A1/en unknown
- 2020-06-11 CL CL2020001564A patent/CL2020001564A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JOP20200149B1 (ar) | 2022-10-30 |
CN111479813A (zh) | 2020-07-31 |
TW201938170A (zh) | 2019-10-01 |
PE20210671A1 (es) | 2021-04-05 |
EP3724192A1 (en) | 2020-10-21 |
SG11202005299VA (en) | 2020-07-29 |
IL275084B2 (en) | 2023-06-01 |
BR112020011880A2 (pt) | 2020-11-24 |
AU2018385724A1 (en) | 2020-07-09 |
CN111479813B (zh) | 2023-03-21 |
JP7428647B2 (ja) | 2024-02-06 |
US20210260072A1 (en) | 2021-08-26 |
PH12020500548A1 (en) | 2021-01-25 |
JOP20200149A1 (ar) | 2020-06-10 |
MX2020006204A (es) | 2020-08-27 |
KR20200100111A (ko) | 2020-08-25 |
CU20200048A7 (es) | 2021-03-11 |
TWI826406B (zh) | 2023-12-21 |
JP2021506821A (ja) | 2021-02-22 |
WO2019116324A1 (en) | 2019-06-20 |
IL275084A (en) | 2020-07-30 |
HUP1700521A2 (en) | 2019-06-28 |
US11298363B2 (en) | 2022-04-12 |
CA3085562A1 (en) | 2019-06-20 |
EA202091344A1 (ru) | 2020-09-09 |
AR113933A1 (es) | 2020-07-01 |
TN2020000083A1 (en) | 2022-01-06 |
HU231206B1 (hu) | 2021-10-28 |
CU24630B1 (es) | 2022-12-12 |
AU2018385724B2 (en) | 2023-05-25 |
EP3724192B1 (en) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020001564A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina. | |
MX2020004405A (es) | Compuestos biciclicos en puente como moduladores del receptor farnesoide x. | |
CL2019001264A1 (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
UY37302A (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
DOP2016000017A (es) | Nuevos compuestos tricíclicos | |
UY31881A (es) | Derivados sustituidos de imidazo[1,5-a]pirrolo[2,3-e]pirazinas e imidazo[1,2-a]pirrolo[2,3-e]pirazinas, sus sales, prodrogas, metabolitos biológicalmente activos, estereoisómeros e isómeros farmacéuticamente aceptables. | |
UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
CL2020001140A1 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x. | |
CO6440569A2 (es) | Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides | |
CL2019001481A1 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos. | |
CL2022000457A1 (es) | Triazolopirimidinas como inhibidores de a2a/a2b. | |
CL2020001817A1 (es) | Moduladores del receptor c5a | |
CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
ECSP19072975A (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
AR127470A1 (es) | Inhibidores de lrrk2 | |
MX2020004339A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
CL2023002635A1 (es) | Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1 | |
MX2020003832A (es) | Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. | |
CL2020000439A1 (es) | Sales de un compuesto y sus formas cristalinas. | |
AR127182A1 (es) | DERIVADOS DE AMINA BICÍCLICOS COMO MODULADORES DE RECEPTOR GABAA a5 | |
UY36023A (es) | “derivados cristalinos de (s)-1-((2r,3r,4s,5s)-5-alil-3-metoxi-4-(tosilmetil) tetrahidrofuran-2-il)-3-aminopropan-2-ol “. | |
ECSP22093794A (es) | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos | |
CO2023013714A2 (es) | Análogos, sales, composiciones y métodos de uso de la psilocibina |